; or (B) any entity that is owned, affiliated, or related under a common ownership structure with an entity described in subparagraph (A). (2) Net price The term net price , with respect to a prescription drug, means the final price paid by a group health plan or health insurance issuer offering group or individual health insurance coverage (or entity that provides pharmacy benefits management services on behalf of such a plan or issuer) after applying any rebates and other remuneration under the plan or coverage from drug manufacturers during the plan year. (e) Specification A health insurance plan will not fail to be treated as an HDHP for complying with the cost-sharing cap in this section. . (b) ERISA (1) In general Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1185 et seq. ) is amended by adding at the end the following: 725. Requirements with respect to cost-sharing for highly rebated drugs (a) In general No later than April 1, 2024, and annually thereafter, the Secretary shall certify (or recertify, if applicable) as a highly rebated drug any drug identified in reports submitted under sections 725, 2799A–10 of the Public Health Service Act, and 9825 of the Internal Revenue Code of 1986 for which total rebates, reductions in price, and other forms of remuneration in the previous year aggregated across all commercial markets exceeded 50 percent of total annual spending on such drug in such year. (b) Deductible and cost-Sharing limitations for certified drugs For plan years that begin on or after January 1, 2025, a group health plan or a health insurance issuer offering group health insurance coverage (or entity that provides pharmacy benefits management services on behalf of such a plan or issuer) that provides coverage of any highly rebated drug shall not impose cost-sharing in excess of, per 30-day supply, the quotient of the annual net price paid by such group health plan or health insurance issuer (or entity that provides pharmacy benefits